^
4d
Guardant Health sues Tempus for patent infringement (Genomeweb)
"Guardant Health filed a lawsuit...against rival cancer genomics firm Tempus AI, alleging that Tempus has infringed a handful of its patents relating to liquid biopsy sequencing methods...Guardant specifically cited Tempus' Tempus xF, Tempus xF+, and Tempus xM Monitor assays as examples, as well as the firm's recently developed minimal residual disease offering, Tempus xM MRD."
Corporate lawsuit • Patent
|
Tempus xF Assay • Tempus xF+ Panel • Tempus xM
16d
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care (Businesswire)
"Tempus...announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation sequencing assays....Tempus is now offering these two IHC tests, which are recommended in clinical guidelines for several cancer types and may be ordered for other cancer types at the clinician's discretion. The new offerings further expand Tempus’ comprehensive portfolio of testing solutions that is designed to help physicians maximize and optimize treatment options for each of their patients."
Clinical data
17d
Tempus exhibits 16 abstracts at the 2024 American Society of Clinical Oncology annual meeting (Tempus Press Release)
"Tempus...announced the company is scheduled to exhibit 16 abstracts at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from May 31-June 4 in Chicago, Illinois. This year, Tempus is presenting its latest research, including new data from its minimal residual disease (MRD) assay, xM."
Clinical data
|
Tempus xM
17d
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC (Businesswire)
"Tempus...today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it difficult for the updates to be rapidly incorporated into patient treatment plans. As part of a larger, strategic collaboration, the two companies are now expanding upon a pilot program that utilizes Next, Tempus’ care pathway intelligence platform, to help physicians determine if their patients with NSCLC may benefit from guideline-directed molecular testing, including testing for epidermal growth factor receptor (EGFR) mutations."
Licensing / partnership
2ms
Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next (Tempus Press Release)
"Tempus...is introducing Tempus Next, a care pathway intelligence platform. By harnessing the power of AI, Tempus Next identifies care gaps and equips clinicians with actionable insights at the point of care, supporting access to the most up-to-date, guideline-directed treatments."
Clinical data
3ms
Tempus announces the clinical launch of p-MSI, its MSI-high predictive algorithm for patients with prostate cancer (Tempus Press Release)
"Tempus...announces the clinical launch of p-MSI, a digital pathology algorithm using H&E whole slide images that is available with the company’s xT assay for patients with prostate cancer. This offering aims to identify patients who may be more likely than the average patient with prostate cancer to have a tumor that is microsatellite instability high (MSI-H), and therefore potentially eligible for immunotherapy."
Launch
|
Tempus xT Assay
3ms
Tempus contributes de-identified cancer data to planned data enclave (Tempus Press Release)
"Tempus...announced a generous data contribution of de-identified tumor profiles with limited associated clinical information from more than 3,000 cancer diagnoses to the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer."
Clinical
3ms
Ambry Genetics announces a collaboration with Tempus to advance paired germline and somatic testing services for medical oncologists (Ambry Genetics Press Release)
"Ambry Genetics...and Tempus...announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services...As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext®️ and CancerNext-Expanded®️ assays...Tempus’ xG and xG+ germline assays are a part of Tempus' extensive portfolio of oncology-focused testing solutions that maximize biomarker detection and identify actionable variants linked to targeted therapy and clinical trial options."
Licensing / partnership
|
CancerNext ® • CancerNext-Expanded® • Tempus xG
4ms
Tempus expanding access to its next-generation sequencing tests as an in-network provider for Cigna (Tempus Press Release)
"Tempus...announced that the company has signed an agreement for in-network provider status with Cigna Healthcare. The collaboration signifies an important stride in enhancing accessibility to Tempus’ array of molecular profiling tests for Cigna’s extensive network, which comprises approximately 16 million members."
Licensing / partnership
5ms
Tempus is now an In-Network provider for Humana, expanding access to its next-generation sequencing tests (Tempus Press Release)
"Tempus...announced that the company has signed agreements for in-network provider status with Humana Inc. Under the agreement, Humana’s over 13 million members will have improved access to Tempus’ portfolio of molecular profiling tests in accordance with their medical policies, expanding precision oncology care throughout the country."
Licensing / partnership
5ms
Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only (Businesswire)
"Tempus...today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions. The tumor-naïve plasma based test is available for research use only to detect circulating tumor DNA (ctDNA) in the blood of patients with early stage CRC after surgery...xM is a liquid biopsy approach to MRD assessment, where no baseline tumor tissue is required...At the 2024 ASCO® Gastrointestinal Cancers Symposium, Tempus is presenting research that demonstrates xM’s ability to detect clinical recurrence of early stage CRC with high clinical specificity (94%) and sensitivity (53%) at a landmark single time point 4 weeks after curative surgery. In addition to the data being presented, Tempus is still running further clinical validation studies, through which it expects these numbers could improve over time."
Clinical data • Circulating tumor DNA
6ms
Tempus announces participation in National Cancer Institute’s ComboMATCH trials (Tempus Press Release)
"Tempus...announced its participation in the National Cancer Institute’s (NCI) ComboMATCH group of precision medicine trials. The ComboMATCH trials aim to pair patients with a therapy that has the potential to manage their tumor and help assist physicians in devising more effective treatment strategies for individuals with locally advanced or advanced solid tumors. Tempus is one of the NCI-designated commercial laboratories for the initiative...Oncologists at participating ComboMATCH clinical sites can leverage their patients’ results from Tempus’ signature xT assay to determine their potential suitability for the program’s treatment trials."
Clinical
|
Tempus xT Assay
7ms
SkylineDx Announces Commercial Collaboration with Tempus to Advance Patient Care with its Merlin Test (PRNewswire)
"SkylineDx...is announcing a strategic commercial collaboration with Tempus, a leader in precision medicine. This collaboration aims to advance patient care by expanding the accessibility to the SkylineDx Merlin™ Test, further solidifying both companies' commitment to improving patient outcomes...The Merlin™ Test is a molecular diagnostic tool developed by SkylineDx, designed to provide personalized insights into early-stage melanoma cancer patients' treatment options....This collaboration marks a significant milestone in the journey to advance precision medicine and personalized healthcare. By combining the strengths of SkylineDx and Tempus, the collaboration is poised to further improve accessibility for patients to the latest medical innovations."
Licensing / partnership
|
Merlin Assay
7ms
Personalis and Tempus enter into a strategic collaboration to advance cancer testing (Personalis Press Release)
"Personalis, Inc...and Tempus Labs, Inc...announced a strategic collaboration to co-commercialize NeXT Personal® Dx, Personalis’ whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is a leap forward in tumor-informed approaches, setting the new standard in performance of MRD tests with unprecedented sensitivity and high specificity. The test was launched by Personalis in October of this year."
Licensing / partnership
|
NeXT Personal™
7ms
Tempus welcomes City of Hope Comprehensive Cancer Center to Tempus+ community (Tempus Press Release)
"Tempus...announced that City of Hope Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers represents over 30 medical centers that are leveraging the program to advance its research."
Licensing / partnership
7ms
Tempus announces Medicare coverage for Tempus|xT across solid tumor and hematologic malignancies (Tempus Press Release)
"Tempus...announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus|xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’ CAP/CLIA laboratory located in Research Triangle Park in North Carolina."
Medicare • Reimbursement
|
Tempus xT Assay
7ms
Tempus announces new strategic collaboration with Recursion to advance therapeutic development (Tempus Press Release)
"Tempus...announced a multi-year, strategic collaboration with Recursion...The two companies are working together to advance biomarker-driven therapeutic development with a data-first approach...Through this collaboration, Recursion has access to Tempus’ library of de-identified, multimodal data to derive insights that have the potential to further Recursion’s therapeutic development."
Licensing / partnership
7ms
Tempus announces research collaboration with Bristol Myers Squibb to apply multimodal AI approaches (Tempus Press Release)
"Tempus...announced a multi-year, strategic research collaboration with Bristol Myers Squibb...The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease models in specific cancer disease areas."
Licensing / partnership
8ms
Tempus announces new ctDNA Assay, xF Monitor (Tempus Press Release)
"Tempus...announced xF Monitor – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy for patients with advanced cancers."
Commercial
|
Tempus xF Monitor assay
8ms
Tempus announces eight abstracts accepted for presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting (Tempus Press Release)
"Tempus...announced eight abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, which convenes in San Diego, California, from November 1-5, 2023."
Clinical data
|
Tempus xF Assay
8ms
Tempus announces five abstracts accepted for presentation at the European Society for Medical Oncology Congress 2023 (Tempus Press Release)
"Tempus...announced five abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2023, which convenes in Madrid, Spain, from October 20-24, 2023."
Clinical data
10ms
Tempus welcomes UNC Lineberger Comprehensive Cancer Center to Tempus+ community (Tempus Press Release)
"Tempus...announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research."
Licensing / partnership
10ms
Tempus to integrate genomic test ordering into CureMD's oncology EHR (Genomeweb)
"CureMD...said Tuesday that it has formed a partnership with Tempus to integrate genomic test workflows into its electronic health records system."
Licensing / partnership
10ms
FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test (Businesswire)
"Tempus...announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test. The test uses a machine learning model to analyze sequence data produced by Tempus’ FDA-approved, next generation sequencing-based xT CDx assay. It is intended to identify cancer patients with solid tumors who may benefit from treatment with specific targeted therapies when a patient’s tumor has experienced allele-specific loss of heterozygosity (LOH) for specific human leukocyte antigen (HLA) Class I alleles."
FDA event
|
Tempus HLA-LOH assay
11ms
Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study (Businesswire)
"Tempus...announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset for patients with NSCLC to facilitate future novel research related to precision medicine, diagnostic development, and biomarker discovery....Patients enrolled in the trial will be studied for up to three years to assess the impact of their underlying tumor biology on disease progression and therapy efficacy. The results of this study will be used for biomarker discovery, including potential use of circulating tumor DNA (ctDNA) testing to measure MRD."
Trial status • Licensing / partnership
|
Tempus xT Assay • Tempus xF Assay
12ms
Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics (Businesswire)
"Tempus...today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics...for the treatment of cancer patients. The collaboration supports TScan’s screening protocol for its Phase 1 solid tumor clinical trial which is designed to enable customized mixtures of TCR-Ts to be administered to patients based on tumor antigen positivity and intact HLA expression...TScan is collaborating with Tempus to use the xT assay, Tempus’ 648-gene panel, to prospectively identify patients with HLA loss in the tumor to select TCR-Ts that recognize HLA genes still intact in the patient’s tumor."
Licensing / partnership
|
Tempus xT Assay
12ms
Tempus launches standalone RNA sequencing test, xR (Tempus Press Release)
"Tempus...introduces its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII."
Launch
|
Tempus xR
1year
Tempus exhibits 20 abstracts at the 2023 American Society of Clinical Oncology annual meeting (Tempus Press Release)
"Tempus...announced the company will exhibit 20 abstracts at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from June 2-6, in Chicago, Illinois. This year, Tempus is presenting its latest research via two oral presentations, one poster discussion session, and several poster presentations."
Clinical data
|
Tempus xT Assay
1year
GeneCentric Therapeutics announces commercial availability of PurISTSM Test for pancreatic cancer (GeneCentric Therap Press Release)
"GeneCentric Therapeutics...announced today that its PurISTSM test is now commercially available through Tempus for clinical use. PurIST is a novel RNA-expression test that identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) who are likely to experience longer overall survival (OS) with standard-of-care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC."
Commercial
|
PurIST℠ Test
1year
Tempus receives U.S. FDA approval for xT CDx, a NGS-based in vitro diagnostic device (Tempus Press Release)
"Tempus...announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx. xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients."
FDA event
|
Tempus xT Assay
1year
Tempus announces seven abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting 2023 (Tempus Press Release)
"Tempus...announced seven abstracts were accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 14-19, in Orlando, Florida. Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research."
Clinical data
1year
Tempus announces second sequencing collaboration with Lilly to expand patient access to genomic testing (Tempus Press Release)
"Tempus...announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus’ molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing."
Licensing / partnership
over1year
Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development (Businesswire)
"Tempus...today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and development in oncology....Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology."
Licensing / partnership
over1year
Tempus announces new multi-omics collaboration with Actuate Therapeutics (Tempus Press Release)
"Tempus...announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc...to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests will be used to help discover and further validate biomarker profiles in patients who may benefit from treatment with elraglusib, a selective GSK-3β inhibitor."
Licensing / partnership
|
Tempus xF+ Panel
|
elraglusib (9-ING-41)
over1year
Tempus announces prospective study for biomarker discovery in small cell lung cancer (Tempus Press Release)
"Tempus...announced a prospective study (NCT05257551), in collaboration with AstraZeneca...that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is currently open for enrollment."
Enrollment open
over1year
Fight colorectal cancer funds Tempus research fellow to identify gaps in colorectal cancer research (Tempus Press Release)
"Fight Colorectal Cancer (Fight CRC) announced today that they have committed $150,000 per year for a three-year research fellowship to study clinical data at Tempus, a leader in artificial intelligence and precision medicine. The awarded researcher will receive access to Tempus de-identified datasets and analytical platform to identify insights and gaps that are occurring in colorectal cancer (CRC) clinical research...Part of the fellowship involves furthering biomarker testing, which has become an indispensable step in treatment planning for colon and rectal cancer patients. The patients’ treatment possibilities have been greatly extended due to the advancements in biomarker testing, although more research is needed to better understand biomarkers."
Licensing / partnership
over1year
Tempus announces real-world data-driven program to accelerate precision oncology research (Tempus Press Release)
"Tempus...announced Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes a number of medical centers that are leveraging the program to advance its research, including Allegheny Health Network, Baylor College of Medicine, Rush University Medical Center, Stanford Cancer Center, TriHealth, UCLA Jonsson Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, and University of North Carolina Lineberger Comprehensive Cancer Center."
Clinical
over1year
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D (Tempus Press Release)
"GSK plc...and Tempus...have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data...The new collaboration builds from the existing relationship between the companies that began in 2020 on clinical trial enrolment of patients with certain types of cancer."
Licensing / partnership
over1year
Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics (Businesswire)
"Tempus...announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics...in support of its ongoing Phase II study of navtemadlin (KRT-232). Tempus’ CDx test, which will be developed on Tempus’ xT platform, will be used to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be eligible for treatment with navtemadlin. Navtemadlin is a potent, selective, orally available MDM2 inhibitor that overcomes MDM2 dysregulation by restoring p53 activity and inducing apoptosis of TP53WT tumor cells."
Licensing / partnership
|
Tempus xT Assay
|
navtemadlin (KRT-232)
over1year
Tempus announces collaboration with the children’s oncology group to expand access to genomic testing for pediatric cancer patients (Tempus Press Release)
"Tempus...announced a collaboration with the Children’s Oncology Group (COG)...to assist with their Pediatric MATCH Screening Trial APEC1621SC (NCT03155620). The Pediatric MATCH Screening Trial is studying the effectiveness of genetic testing-directed treatment in pediatric patients with solid tumors, non-Hodgkin lymphomas, and histiocytic disorders...Through this collaboration, Tempus will provide genomic sequencing for up to 300 eligible patients per year between 12 months and 21-years-old with recurrent or refractory solid tumors. Treating physicians have access to Tempus’ xT assay to help determine if a patient is a likely match for the Pediatric MATCH Screening Trial."
Licensing / partnership
|
Tempus xT Assay
almost2years
Tempus announces three abstracts accepted for presentation at the European Society for Medical Oncology Congress 2022 (Tempus Press Release)
"Tempus...announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations."
Clinical data
|
Tempus xT Assay • Tempus TO
almost2years
Tempus announces research collaboration with Intermountain Healthcare to advance precision oncology research (Tempus Press Release)
"Tempus...announced a collaboration with Intermountain Healthcare...which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients...Intermountain Healthcare is leveraging Tempus’ solid tumor/normal genomic test, xT, to generate whole transcriptomic data on existing samples for research purposes."
Licensing / partnership
|
Tempus xT Assay